Sorafenib

You have access
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma
ATSUO KITAOKA, KYOKO OURA, KOJI FUJITA, KOTA SASAKI, FUMIYUKI SUETSUGU, MAI NAKAHARA, TOMOKO TADOKORO, SHIMA MIMURA, JOJI TANI, ASAHIRO MORISHITA, ERIKA OMAYU, HISAKAZU IWAMA, TSUTOMU MASAKI and HIDEKI KOBARA

Anticancer Research October 2025, 45 (10) 4211-4229; DOI: https://doi.org/10.21873/anticanres.17773
You have access
Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
SHOHEI KOMATSU, YOSHIHIKO YANO, TAKUYA MIMURA, AKIHIRO MINAMI, KENJI MOMOSE, HIROTAKA HIRANO, MOTOFUMI TANAKA, YUKI UEDA, KENTARO TAI, YUKI YASUHARA, DAISUKE NAKAGAWA, ATSUSHI YAMAMOTO, MASAHIRO KIDO, YOSHIHIDE UEDA, YUZO KODAMA and TAKUMI FUKUMOTO

Anticancer Research July 2024, 44 (7) 3097-3103; DOI: https://doi.org/10.21873/anticanres.17123
Open Access
Ex Vivo Evaluation of Antiangiogenic Drugs in Oral Cancer: Potential Implications for Targeting Vasculogenic Mimicry
ROOSA HUJANEN, TUULA SALO, KARI K. EKLUND and ABDELHAKIM SALEM

Anticancer Research June 2024, 44 (6) 2377-2392; DOI: https://doi.org/10.21873/anticanres.17045
You have access
Lenvatinib Versus Sorafenib in Advanced Hepatic Cell Carcinoma: A Double Center Retrospective Analysis
GIOVANNI ANTONIO MARROCCO, MARIANNA SILLETTA, VINCENZO BIANCO, FRANCESCO MONDERA, CAROLINA SCIORTINO, LAURA PAPPALARDO, VALENTINA VIGLIALORO, ENRICO CORTESI, GIUSEPPE TONINI and SALVATORE CAPONNETTO

Anticancer Research February 2023, 43 (2) 755-763; DOI: https://doi.org/10.21873/anticanres.16215
You have access
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
KAZUTO TAJIRI, YOSHIHARU TOKIMITSU, KENGO KAWAI, YUCHI MOTOFUJI, EIJI SHINNO, YOSHIRO KASHII, NOZOMU MURAISHI, AIKO MURAYAMA, YUKA HAYASHI, MASAMI MINEMURA, TERUMI TAKAHARA, YUKIHIRO SHIMIZU and ICHIRO YASUDA

Anticancer Research December 2022, 42 (12) 6007-6018; DOI: https://doi.org/10.21873/anticanres.16112
You have access
Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery
SATORU SEO, ETSURO HATANO, MASASHI KANAI, KOHEI OGAWA, YASUTSUGU TAKADA, SHOGO KOBAYASHI, HIDETOSHI EGUCHI, HIROAKI NAGANO and TATSUYA IOKA

Anticancer Research December 2022, 42 (12) 6127-6134; DOI: https://doi.org/10.21873/anticanres.16126
You have access
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study
CHING-TSO CHEN, CHIH-HUNG HSU, ANN-LII CHENG and YU-YUN SHAO

Anticancer Research September 2022, 42 (9) 4461-4470; DOI: https://doi.org/10.21873/anticanres.15946
You have access
Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy
CHIA-HSUN HSIEH, CHAU-TING YEH, YA-HUI HUANG and MING-WEI LAI

Anticancer Research May 2022, 42 (5) 2479-2486; DOI: https://doi.org/10.21873/anticanres.15726
Open Access
Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer
SUNIL KUMAR SURAPANENI, EBONY NOTTINGHAM, ARINDAM MONDAL, NILKUMAR PATEL, PEGGY ARTHUR, ARAGAW GEBEYEHU, ANIL KUMAR KALVALA, ARUN K. RISHI and MANDIP SINGH

Anticancer Research September 2021, 41 (9) 4215-4228; DOI: https://doi.org/10.21873/anticanres.15226
You have access
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma
KAZUKI MAESAKA, RYOTARO SAKAMORI, RYOKO YAMADA, YUKI TAHATA, KAZUYOSHI OHKAWA, MASAHIDE OSHITA, SHINJI TAMURA, HIDEKI HAGIWARA, EIJI MITA, TAKAYUKI YAKUSHIJIN, MASAMI INADA, TAKAHIRO KODAMA, HAYATO HIKITA, TOMOHIDE TATSUMI and TETSUO TAKEHARA

Anticancer Research April 2021, 41 (4) 2187-2192; DOI: https://doi.org/10.21873/anticanres.14993

Main menu

User menu

Search

Sorafenib

Pages